Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.

By Yanyan Zhu, Bhavik J. Pandya, Hyon K. Choi. American Journal of Medicine, 2012

619 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Nephrology, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/145964a245efa87b8b21b77b3bb74832b4a45937

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. M. Chen-Xu
2. M. Pillinger
3. Hyon K. Choi
4. Sharan K. Rai
5. C. Yokose

In Nephrology

1. M. Chen-Xu
2. M. Pillinger
3. Hyon K. Choi
4. Sharan K. Rai
5. C. Yokose

In Nutrition and Dietetics

1. M. Chen-Xu
2. M. Pillinger
3. Hyon K. Choi
4. Sharan K. Rai
5. C. Yokose

Citations in the corpus

• 2016 updated EULAR evidence-based recommendations for the management of gout (2014, neutral): “51 52 In a US population-based study, the prevalence of CKD (stage ≥ 2) in patients with SUA level ≥ 10 mg/dL (594.9 μ mol/L) and in patients with gout was 86% and 53%, respectively.”
• Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007-2016 (2019, methodology): “We also used sexspecific definitions of hyperuricemia to allow comparisons based on laboratory definitions from previous studies (11,39).”